Veracyte Announces Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Veracyte (VCYT) Tops Q3 EPS by 13c, Revenues Beat; Boosts FY18 Revenue Outlook
October 29, 2018 4:30 PM EDTVeracyte (NASDAQ: VCYT) reported Q3 EPS of ($0.12), $0.13 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $21.5 million.
Revenue was $23.5 million, an increase of 34 percent;Genomic test volume was 8,006, an increase of 23 percent;Gross margin was 65 percent, an increase of 6 percent;Operating expenses,... More